<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Approximately half of <z:hpo ids='HP_0000001'>all</z:hpo> human genes use alternative transcription start sites (TSSs) to control <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels and broaden the transcriptional output in healthy tissues </plain></SENT>
<SENT sid="1" pm="."><plain>Aberrant expression patterns promoting <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, however, may arise from alternative promoter usage </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: By profiling 108 colorectal samples using exon arrays, we identified nine genes (TCF12, OSBPL1A, TRAK1, ANK3, CHEK1, UGP2, LMO7, ACSL5, and SCIN) showing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific alternative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TSS</z:e> usage in both <z:mpath ids='MPATH_270'>adenoma</z:mpath> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> samples relative to <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa </plain></SENT>
<SENT sid="3" pm="."><plain>Analysis of independent exon array data sets corroborated these findings </plain></SENT>
<SENT sid="4" pm="."><plain>Additionally, we confirmed the observed patterns for selected <z:chebi fb="2" ids="33699">mRNAs</z:chebi> using quantitative real-time reverse-transcription PCR </plain></SENT>
<SENT sid="5" pm="."><plain>Interestingly, for some of the genes, the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TSS</z:e> usage was not restricted to <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>A comprehensive survey of the nine genes in lung, bladder, liver, prostate, gastric, and <z:e sem="disease" ids="C0153633" disease_type="Neoplastic Process" abbrv="">brain cancer</z:e> revealed significantly altered <z:chebi fb="2" ids="33699">mRNA</z:chebi> isoform ratios for CHEK1, OSBPL1A, and TCF12 in a subset of these <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types.To identify the mechanism responsible for the shift in alternative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TSS</z:e> usage, we antagonized the Wnt-signaling pathway in DLD1 and Ls174T <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines, which remarkably led to a shift in the preferred <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TSS</z:e> for both OSBPL1A and TRAK1 </plain></SENT>
<SENT sid="7" pm="."><plain>This indicated a regulatory role of the Wnt pathway in selecting <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TSS</z:e>, possibly also involving TP53 and SOX9, as their transcription binding sites were enriched in the promoters of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> preferred isoforms together with their <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels being increased in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples </plain></SENT>
<SENT sid="8" pm="."><plain>Finally, to evaluate the prognostic impact of the altered <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TSS</z:e> usage, immunohistochemistry was used to show deregulation of the total protein levels of both TCF12 and OSBPL1A, corresponding to the <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels observed </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, the level of nuclear TCF12 had a significant correlation to progression free survival in a cohort of 248 stage II <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> samples </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Alternative <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">TSS</z:e> usage in colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> samples has been shown for nine genes, and OSBPL1A and TRAK1 were found to be regulated in vitro by Wnt signaling </plain></SENT>
<SENT sid="11" pm="."><plain>TCF12 protein expression was upregulated in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> samples and correlated with progression free survival </plain></SENT>
</text></document>